Is there a generic for Xarelto available now?
No generic version of Xarelto (rivaroxaban) is available in the US market as of late 2024. Bayer holds ongoing patent protection and exclusivity, blocking FDA approval of generics despite ANDA filings from multiple companies.[1][2]
When does Xarelto's main patent expire?
The primary composition-of-matter patent for Xarelto (US Patent 7,157,456) expires June 2, 2024, but key method-of-use patents extend protection through at least 2026, with pediatric exclusivity pushing some to 2028. Additional formulation and process patents remain active until 2032 or later.[2][3]
Which companies filed for generic Xarelto and when?
Mylan (now Viatris), Sandoz, and others submitted ANDA Paragraph IV challenges starting in 2016, triggering Bayer's patent lawsuits. The first tentative approval went to Alembic in 2021, but launch is delayed by a 2023 settlement allowing entry no earlier than 2026, pending court outcomes.[2][4]
What delays generic entry past 2024?
Bayer won key patent rulings, including on crushable tablets (2023), and settlements with generic makers stagger launches: some as early as March 2026, others later. Ongoing litigation at the Federal Circuit could shift timelines.[2][3][4]
Is generic Xarelto available outside the US?
Yes, in Europe since 2020 (e.g., from Accord, Arrow), Canada since 2023, and India. US patients cannot import these due to FDA rules; availability remains US-specific.[1][5]
How does this affect patients and costs?
Xarelto lists at $500+ for a 30-day supply, with no generic discounts yet. Patient assistance programs from Bayer or copay cards help, but full generic entry could cut costs 80-90% based on prior blood thinners.[1][2]
[1]: FDA Orange Book for rivaroxaban
[2]: DrugPatentWatch.com - Xarelto patents and generics
[3]: USPTO Patent Term for rivaroxaban
[4]: FiercePharma - Xarelto generic settlements
[5]: EMA - Rivaroxaban generics